337 related articles for article (PubMed ID: 9218984)
1. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
Fariello RG
Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
[No Abstract] [Full Text] [Related]
2. [Nootropic drugs: definition, classification, mechanism of action, clinical effectiveness, substances].
Kuhlmey J
Z Arztl Fortbild (Jena); 1994 Sep; 88(9):697-701. PubMed ID: 7975756
[No Abstract] [Full Text] [Related]
3. [Possibilities and limits of therapy of cognition disorders in the elderly].
Hoyer S
Z Gerontol Geriatr; 1995; 28(6):457-62. PubMed ID: 8581765
[TBL] [Abstract][Full Text] [Related]
4. Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias.
Masterman D
Clin Geriatr Med; 2004 Feb; 20(1):59-68. PubMed ID: 15062487
[No Abstract] [Full Text] [Related]
5. Galantamine for Alzheimer's disease and mild cognitive impairment.
Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
[No Abstract] [Full Text] [Related]
6. [Challenging pharmacotherapy in dementia].
Ihl R
MMW Fortschr Med; 2009 Mar; 151(13):46-8. PubMed ID: 19504818
[No Abstract] [Full Text] [Related]
7. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Ferris SH; Lucca U; Mohs R; Dubois B; Wesnes K; Erzigkeit H; Geldmacher D; Bodick N
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():34-8. PubMed ID: 9305514
[No Abstract] [Full Text] [Related]
8. Donepezil-induced nightmares in mild cognitive impairment.
Kitabayashi Y; Ueda H; Tsuchida H; Yamashita T; Narumoto J; Fukui K
Psychiatry Clin Neurosci; 2006 Feb; 60(1):123-4. PubMed ID: 16472374
[No Abstract] [Full Text] [Related]
9. Drugs for cognitive loss and dementia.
Treat Guidel Med Lett; 2010 Mar; 8(91):19-24. PubMed ID: 20179667
[No Abstract] [Full Text] [Related]
10. Measuring cognitive change in Alzheimer's disease clinical drug trials.
Harrison JE
J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
[TBL] [Abstract][Full Text] [Related]
11. Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Feldman H; Anand R; Blesa R; Dubois B; Gray J; Homma A; Mohr E; Morris JC; Parys W; Raschig A; Robillard A
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():61-4. PubMed ID: 9305520
[No Abstract] [Full Text] [Related]
12. Dementia.
Warner J; Butler R
Clin Evid; 2002 Jun; (7):846-66. PubMed ID: 12230710
[No Abstract] [Full Text] [Related]
13. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
Tariska P; Paksy A
Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
[TBL] [Abstract][Full Text] [Related]
14. Outcomes for clinical trials in mild-to-moderate dementia to evaluate drugs with presumably symptomatic effects.
Frolich L
J Nutr Health Aging; 2007; 11(4):357-8. PubMed ID: 17653499
[No Abstract] [Full Text] [Related]
15. Recognizing apathy in Alzheimer's disease.
Lerner AJ; Strauss M; Sami SA
Geriatrics; 2007 Nov; 62(11):14-7. PubMed ID: 17999565
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive approach of donepezil and psychosocial interventions on cognitive function and quality of life for Alzheimer's disease: the Osaki-Tajiri Project.
Meguro M; Kasai M; Akanuma K; Ishii H; Yamaguchi S; Meguro K
Age Ageing; 2008 Jul; 37(4):469-73. PubMed ID: 18515851
[No Abstract] [Full Text] [Related]
17. Utilization of the Dementia Rating Scale-2 and cognitive enhancers in the diagnosis and treatment of cognitive disorders and dementia.
Caston JC; Diehl LA; Hedgepath AW
J S C Med Assoc; 2004 Feb; 100(2):32-8. PubMed ID: 15040232
[No Abstract] [Full Text] [Related]
18. Safety of nicergoline as an agent for management of cognitive function disorders.
Saletu B; Garg A; Shoeb A
Biomed Res Int; 2014; 2014():610103. PubMed ID: 25243157
[TBL] [Abstract][Full Text] [Related]
19. [Alzheimer drugs for mild cognitive impairment].
Fellgiebel A
Neuropsychiatr; 2007; 21(3):230-3. PubMed ID: 17915184
[TBL] [Abstract][Full Text] [Related]
20. Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Post SG; Beerman B; Brodaty H; Gaines AW; Gauthier SG; Geldmacher DS; Hill S; Homma A; Rossor MN; Whitehouse PJ; Winblad B
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():26-8. PubMed ID: 9305511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
